Journal Article
. 2021 Feb; 25(8):4001-4013.
doi: 10.1111/jcmm.16363.

Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis

Hiroyuki Ogawa 1 Kosuke Kaji 1 Norihisa Nishimura 1 Hirotetsu Takagi 1 Koji Ishida 1 Hiroaki Takaya 1 Hideto Kawaratani 1 Kei Moriya 1 Tadashi Namisaki 1 Takemi Akahane 1 Hitoshi Yoshiji 1 
Affiliations
  • PMID: 33609067
  •     53 References
  •     3 citations

Abstract

Molecular targeted agents are pharmacologically used to treat liver fibrosis and have gained increased attention. The present study examined the preventive effect of lenvatinib on experimental liver fibrosis and sinusoidal capillarization as well as the in vitro phenotypes of hepatic stellate cells. LX-2, a human stellate cell line, was used for in vitro studies. In vivo liver fibrosis was induced in F344 rats using carbon tetrachloride by intraperitoneal injection for 8 weeks, and oral administration of lenvatinib was started two weeks after initial injection of carbon tetrachloride. Lenvatinib restrained proliferation and promoted apoptosis of LX-2 with suppressed phosphorylation of extracellular signal-regulated kinase 1/2 and AKT. It also down-regulated COL1A1, ACTA2 and TGFB1 expressions by inhibiting the transforming growth factor-β1/Smad2/3 pathway. Treatment with lenvatinib also suppressed platelet-derived growth factor-BB-stimulated proliferation, chemotaxis and vascular endothelial growth factor-A production, as well as basic fibroblast growth factor-induced LX-2 proliferation. In vivo study showed that lenvatinib attenuated liver fibrosis development with reduction in activated hepatic stellate cells and mRNA expression of profibrogenic markers. Intrahepatic neovascularization was ameliorated with reduced hepatic expressions of Vegf1, Vegf2 and Vegfa in lenvatinib-treated rats. Collectively, these results suggest the potential use of lenvatinib as a novel therapeutic strategy for liver fibrosis.

Keywords: PDGF; VEGF; angiogenesis; hepatic stellate cell; lenvatinib; liver fibrosis.

Hepatic stellate cells and liver fibrosis.
Juan E Puche, Yedidya Saiman, Scott L Friedman.
Compr Physiol, 2013 Nov 23; 3(4). PMID: 24265236
Highly Cited. Review.
Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis.
Yuki Tsuji, Kosuke Kaji, +10 authors, Hitoshi Yoshiji.
Microorganisms, 2020 Jun 25; 8(6). PMID: 32575352    Free PMC article.
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives.
Natascha Roehlen, Emilie Crouchet, Thomas F Baumert.
Cells, 2020 Apr 09; 9(4). PMID: 32260126    Free PMC article.
Review.
Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.
Romain Coriat, Hervé Gouya, +8 authors, François Goldwasser.
PLoS One, 2011 Feb 23; 6(2). PMID: 21340026    Free PMC article.
Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.
Masahiro Matsuki, Taisuke Hoshi, +4 authors, Junji Matsui.
Cancer Med, 2018 May 08; 7(6). PMID: 29733511    Free PMC article.
New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials.
Kai Qu, Zichao Huang, +5 authors, Chang Liu.
Front Pharmacol, 2016 Feb 03; 6. PMID: 26834633    Free PMC article.
Review.
Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
Takayuki Kimura, Yu Kato, +10 authors, Kenichi Nomoto.
Cancer Sci, 2018 Nov 18; 109(12). PMID: 30447042    Free PMC article.
Hepatic stellate cells as key target in liver fibrosis.
Takaaki Higashi, Scott L Friedman, Yujin Hoshida.
Adv Drug Deliv Rev, 2017 May 17; 121. PMID: 28506744    Free PMC article.
Highly Cited. Review.
Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling.
Ikuo Nakamura, Kais Zakharia, +8 authors, Lewis R Roberts.
PLoS One, 2014 Apr 09; 9(4). PMID: 24710173    Free PMC article.
Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases.
Claudia Paternostro, Ezio David, Erica Novo, Maurizio Parola.
World J Gastroenterol, 2010 Jan 19; 16(3). PMID: 20082471    Free PMC article.
Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice.
Piotr Czochra, Borut Klopcic, +8 authors, Stephan Kanzler.
J Hepatol, 2006 Jul 18; 45(3). PMID: 16842882
Liver sinusoidal endothelial cells: Physiology and role in liver diseases.
Johanne Poisson, Sara Lemoinne, +4 authors, Pierre-Emmanuel Rautou.
J Hepatol, 2016 Jul 18; 66(1). PMID: 27423426
Highly Cited. Review.
Hepatocellular Carcinoma: Etiology and Current and Future Drugs.
Aastha Jindal, Anusha Thadi, Kunwar Shailubhai.
J Clin Exp Hepatol, 2019 Apr 27; 9(2). PMID: 31024205    Free PMC article.
Highly Cited. Review.
Selective deletion of hepatocyte platelet-derived growth factor receptor α and development of liver fibrosis in mice.
Beom Jin Lim, Woon-Kyu Lee, +4 authors, Jung Il Lee.
Cell Commun Signal, 2018 Dec 05; 16(1). PMID: 30509307    Free PMC article.
The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study.
M Pinter, W Sieghart, +3 authors, M Peck-Radosavljevic.
Aliment Pharmacol Ther, 2011 Oct 29; 35(1). PMID: 22032637
Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?
Kai Qu, Tian Liu, +8 authors, Chang Liu.
Oncotarget, 2016 Sep 03; 7(41). PMID: 27588502    Free PMC article.
Review.
Serum platelet-derived growth factor BB levels: a potential biomarker for the assessment of liver fibrosis in patients with chronic hepatitis B.
Jiyuan Zhou, Yongqiong Deng, +3 authors, China HepB-Related Fibrosis Assessment Research Group.
Int J Infect Dis, 2016 Jun 14; 49. PMID: 27292607
CD248/endosialin critically regulates hepatic stellate cell proliferation during chronic liver injury via a PDGF-regulated mechanism.
Annika Wilhelm, Victoria Aldridge, +10 authors, Philip N Newsome.
Gut, 2015 Jun 17; 65(7). PMID: 26078290    Free PMC article.
Mammalian target of rapamycin mediates the angiogenic effects of leptin in human hepatic stellate cells.
Sara Aleffi, Nadia Navari, +6 authors, Fabio Marra.
Am J Physiol Gastrointest Liver Physiol, 2011 Jan 22; 301(2). PMID: 21252047
Expression and function of fibroblast growth factor (FGF) 9 in hepatic stellate cells and its role in toxic liver injury.
Marianne Antoine, Werner Wirz, +5 authors, Paul Kiefer.
Biochem Biophys Res Commun, 2007 Jul 31; 361(2). PMID: 17662249
Mechanisms of hepatic stellate cell activation.
Takuma Tsuchida, Scott L Friedman.
Nat Rev Gastroenterol Hepatol, 2017 May 11; 14(7). PMID: 28487545
Highly Cited. Review.
Regulation of Hepatic Stellate Cells and Fibrogenesis by Fibroblast Growth Factors.
Justin D Schumacher, Grace L Guo.
Biomed Res Int, 2016 Oct 05; 2016. PMID: 27699175    Free PMC article.
Review.
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Masatoshi Kudo, Richard S Finn, +19 authors, Ann-Lii Cheng.
Lancet, 2018 Feb 13; 391(10126). PMID: 29433850
Highly Cited.
Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats.
Hitoshi Yoshiji, Ryuichi Noguchi, +7 authors, Hiroshi Fukui.
Am J Physiol Gastrointest Liver Physiol, 2004 Dec 25; 288(5). PMID: 15618280
Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-beta with a combination of imatinib mesylate and ACE inhibitor in rats.
Hitoshi Yoshiji, Shigeki Kuriyama, +11 authors, Hiroshi Fukui.
Int J Mol Med, 2006 Apr 06; 17(5). PMID: 16596278
Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis.
Hiroyuki Ogawa, Kosuke Kaji, +8 authors, Hitoshi Yoshiji.
J Cell Mol Med, 2021 Feb 21; 25(8). PMID: 33609067    Free PMC article.
Low-molecular-weight fibroblast growth factor 2 attenuates hepatic fibrosis by epigenetic down-regulation of Delta-like1.
Ruo-Lang Pan, Li-Xin Xiang, +4 authors, Jian-Zhong Shao.
Hepatology, 2014 Dec 17; 61(5). PMID: 25501710
Vatalanib, a tyrosine kinase inhibitor, decreases hepatic fibrosis and sinusoidal capillarization in CCl4-induced fibrotic mice.
Ling-Jian Kong, Hao Li, +4 authors, Jing Chen.
Mol Med Rep, 2017 Apr 28; 15(5). PMID: 28447731    Free PMC article.
A global view of hepatocellular carcinoma: trends, risk, prevention and management.
Ju Dong Yang, Pierre Hainaut, +3 authors, Lewis R Roberts.
Nat Rev Gastroenterol Hepatol, 2019 Aug 24; 16(10). PMID: 31439937    Free PMC article.
Highly Cited. Review.
Hepatic fibrosis: A convergent response to liver injury that is reversible.
Shuang Wang, Scott L Friedman.
J Hepatol, 2020 May 14; 73(1). PMID: 32402525
Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases.
Feng Liu, George Bayliss, Shougang Zhuang.
Clin Sci (Lond), 2019 Jun 21; 133(12). PMID: 31217321    Free PMC article.
Review.
Investigation of the freely available easy-to-use software 'EZR' for medical statistics.
Y Kanda.
Bone Marrow Transplant, 2012 Dec 05; 48(3). PMID: 23208313    Free PMC article.
Highly Cited.
The STAT3 inhibitor S3I-201 suppresses fibrogenesis and angiogenesis in liver fibrosis.
Zhuo Wang, Jia'an Li, +2 authors, Hongmin Zhang.
Lab Invest, 2018 Sep 13; 98(12). PMID: 30206312
STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib.
Yan-Ru Deng, Hong-Di Ma, +9 authors, Zhe-Xiong Lian.
J Autoimmun, 2013 Aug 21; 46. PMID: 23948302
Liver cirrhosis.
Emmanuel A Tsochatzis, Jaime Bosch, Andrew K Burroughs.
Lancet, 2014 Feb 01; 383(9930). PMID: 24480518
Highly Cited. Review.
Peroxisome proliferator-activated receptor-γ interrupts angiogenic signal transduction by transrepression of platelet-derived growth factor-β receptor in hepatic stellate cells.
Feng Zhang, Desong Kong, +5 authors, Shizhong Zheng.
J Cell Sci, 2013 Nov 22; 127(Pt 2). PMID: 24259663
Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo.
Feng Hong, Hsini Chou, Maria Isabel Fiel, Scott L Friedman.
Dig Dis Sci, 2012 Aug 25; 58(1). PMID: 22918681    Free PMC article.
Disruption of negative feedback loop between vasohibin-1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats.
Laura Coch, Marc Mejias, +5 authors, Mercedes Fernandez.
Hepatology, 2014 Jan 07; 60(2). PMID: 24390792
New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis.
Yan Wang, Juncha Gao, +3 authors, Huiqing Jiang.
J Hepatol, 2010 May 08; 53(1). PMID: 20447716
Mechanisms of hepatic fibrogenesis.
Ursula E Lee, Scott L Friedman.
Best Pract Res Clin Gastroenterol, 2011 Apr 19; 25(2). PMID: 21497738    Free PMC article.
Highly Cited. Review.
NP603, a novel and potent inhibitor of FGFR1 tyrosine kinase, inhibits hepatic stellate cell proliferation and ameliorates hepatic fibrosis in rats.
Nan Lin, Si Chen, +3 authors, Ruiyun Xu.
Am J Physiol Cell Physiol, 2011 May 06; 301(2). PMID: 21543745
Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.
Taisuke Hoshi, Saori Watanabe Miyano, +6 authors, Yasuhiro Funahashi.
Biochem Biophys Res Commun, 2019 Apr 05; 513(1). PMID: 30944079
Fibroblast growth factor 2 (FGF2) regulates cytoglobin expression and activation of human hepatic stellate cells via JNK signaling.
Misako Sato-Matsubara, Tsutomu Matsubara, +10 authors, Norifumi Kawada.
J Biol Chem, 2017 Sep 17; 292(46). PMID: 28916723    Free PMC article.
Functional aspects on the pathophysiology of portal hypertension in cirrhosis.
Juan-Carlos García-Pagán, Jorge Gracia-Sancho, Jaume Bosch.
J Hepatol, 2012 Apr 17; 57(2). PMID: 22504334
Review.
What's new in liver fibrosis? The origin of myofibroblasts in liver fibrosis.
Keiko Iwaisako, David A Brenner, Tatiana Kisseleva.
J Gastroenterol Hepatol, 2012 Feb 15; 27 Suppl 2. PMID: 22320919    Free PMC article.
Review.
Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
Elena De Mattia, Erika Cecchin, +5 authors, Giuseppe Toffoli.
World J Gastroenterol, 2019 Aug 16; 25(29). PMID: 31413525    Free PMC article.
Review.
Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines In Vitro and In Vivo.
Sachiko Ogasawara, Yutaro Mihara, +3 authors, Hirohisa Yano.
Anticancer Res, 2019 Nov 11; 39(11). PMID: 31704822
PDGF receptor-α promotes TGF-β signaling in hepatic stellate cells via transcriptional and posttranscriptional regulation of TGF-β receptors.
Chunsheng Liu, Jiachu Li, +5 authors, Ningling Kang.
Am J Physiol Gastrointest Liver Physiol, 2014 Aug 30; 307(7). PMID: 25169976    Free PMC article.
Lyn kinase enhanced hepatic fibrosis by modulating the activation of hepatic stellate cells.
Yin Li, Lin Xiong, Jianping Gong.
Am J Transl Res, 2017 Jul 04; 9(6). PMID: 28670375    Free PMC article.
The role of hypercoagulability in liver fibrogenesis.
Quentin M Anstee, Ameet Dhar, Mark R Thursz.
Clin Res Hepatol Gastroenterol, 2011 May 17; 35(8-9). PMID: 21570930
Review.
Pathobiology of liver fibrosis: a translational success story.
Youngmin A Lee, Michael C Wallace, Scott L Friedman.
Gut, 2015 Feb 15; 64(5). PMID: 25681399    Free PMC article.
Highly Cited. Review.
Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib.
Yuqing Liu, Zhuo Wang, +7 authors, Tao Ye.
J Hepatol, 2011 Jan 22; 55(3). PMID: 21251937
Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake.
Kosuke Kaji, Norihisa Nishimura, +9 authors, Hitoshi Yoshiji.
Int J Cancer, 2017 Dec 06; 142(8). PMID: 29205334
Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis.
Hiroyuki Ogawa, Kosuke Kaji, +8 authors, Hitoshi Yoshiji.
J Cell Mol Med, 2021 Feb 21; 25(8). PMID: 33609067    Free PMC article.
Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study.
Qi Li, Mengran Cao, +9 authors, Jinzhang Chen.
Front Oncol, 2022 Mar 15; 12. PMID: 35280760    Free PMC article.
Prognostic role of multiparameter MRI and radiomics in progression of advanced unresectable hepatocellular carcinoma following combined transcatheter arterial chemoembolization and lenvatinib therapy.
Junpeng Luo, Zhimei Huang, +2 authors, Jinhua Huang.
BMC Gastroenterol, 2022 Mar 10; 22(1). PMID: 35260095    Free PMC article.